Molecular-targeted therapies: lessons from years of clinical development

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Molecular-targeted therapies complement traditional cytotoxic and anti-endocrine treatments for cancer.
• These therapies aim to disrupt specific molecular pathways driving cancer growth and survival.
• Successful targeted agents underscore the importance of target identification and validation.

Purpose of the Study:

• To review the development of major molecular-targeted, non-cytotoxic anticancer agents.
• To highlight key lessons learned from the clinical development of these novel therapies.
• To propose future directions for molecular-targeted drug development in oncology.

Main Methods:

• Review of scientific literature on molecular-targeted therapies in cancer treatment.
• Analysis of main molecular targets utilized in anticancer drug development.
• Examination of clinical development pathways and outcomes for targeted agents.

Main Results:

• Key molecular targets include cell surface receptors, signal transduction pathways, gene transcription, ubiquitin-proteasome/heat shock proteins, and tumor microenvironment components.
• Antiangiogenic agents represent a significant component of targeted therapies.
• Development of targeted therapies has yielded valuable insights into drug efficacy and safety.

Conclusions:

• Molecular-targeted therapies represent a significant advancement in cancer treatment.
• Continued focus on target validation and understanding cancer biology is crucial for future drug development.
• Exploring new horizons in clinical development will enhance the effectiveness of targeted anticancer strategies.